Semaglutide: First Global Approval.
Drugs
February 1, 2018
Sohita Dhillon
Journal ArticleReviewHuman Study
Extracted Claims (4)
| Intervention | Direction | Endpoint | Population | Dosage | Impact | Claim # |
|---|---|---|---|---|---|---|
subcutaneous formulation of semaglutide (Ozempic) | decrease | body weight | patients with type 2 diabetes | 15% | reduced | #1 |
subcutaneous formulation of semaglutide (Ozempic) | decrease | HbA1c levels | patients with type 2 diabetes | 1.5% | lowered | #2 |
subcutaneous formulation of semaglutide (Ozempic) | increase | cardiovascular outcomes | patients with type 2 diabetes | - | improved | #3 |
subcutaneous formulation of semaglutide (Ozempic) | no change | kidney function | patients with type 2 diabetes | - | showed no significant effect | #4 |
Abstract
Novo Nordisk has developed a subcutaneous formulation of semaglutide (Ozempic
Medical Subject Headings (MeSH)
Blood GlucoseDiabetes Mellitus, Type 2Drug ApprovalGlucagon-Like PeptidesHumansHypoglycemic AgentsInsulin
Study Links
PubMed ID29363040
Related Supplements